Zheng Quan Shi Bao Wang·2025-06-24 12:20Group 1 - The core focus of the company is on three major directions: digital intelligence technology, life sciences, and green technology, aiming to develop core capabilities and establish industry leaders in sectors such as biomanufacturing, synthetic biology, healthcare, artificial intelligence, and clean energy [1][2] - The company has established a development model of "R&D cultivation + industrial mergers and acquisitions + professional operations" to serve as a strategic platform for the development of emerging industries within the group [1][2] - The company has invested over 60 billion yuan in a private placement for Kaisa Bio and is collaborating with the Hefei municipal government to establish a biobased composite materials production and R&D base, which is set to begin trial production in August [2] Group 2 - In the digital intelligence sector, the company has become the largest shareholder of Ruichi Information through a joint investment with ARM, and has established seven R&D platforms in collaboration with top universities and research institutions, with a budget of 350 million yuan for R&D [2] - In the life sciences sector, the company is investing 11.8 billion yuan to strategically acquire a majority stake in Renfu Pharmaceutical, which has multiple national and provincial-level technology platforms [2] - The company reported a revenue of 52.7 billion yuan from strategic emerging industries in 2024, reflecting a year-on-year growth of 14.7% [3]